(Q54375138)

29 May 2018

title

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. (English)

1 reference

29 May 2018

main subject

phase II clinical trial

0 references

1 reference

Christian H. Ottensmeier

9

1 reference

29 May 2018

Paul Lorigan

10

1 reference

29 May 2018

author name string

A Gupta

1

1 reference

29 May 2018

S Love

2

1 reference

29 May 2018

A Schuh

3

1 reference

29 May 2018

M Shanyinde

4

1 reference

29 May 2018

J M Larkin

5

1 reference

29 May 2018

R Plummer

6

1 reference

29 May 2018

P D Nathan

7

1 reference

29 May 2018

S Danson

8

1 reference

29 May 2018

L Collins

11

1 reference

29 May 2018

A Wise

12

1 reference

29 May 2018

R Asher

13

1 reference

29 May 2018

R Lisle

14

1 reference

29 May 2018

M R Middleton

15

1 reference

29 May 2018

publication date

24 February 2014

1 reference

29 May 2018

published in

Annals of Oncology

1 reference

29 May 2018

volume

25

1 reference

29 May 2018

issue

5

1 reference

29 May 2018

page(s)

968-974

1 reference

29 May 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU054

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU054

1 reference

29 May 2018

1 reference

29 May 2018